At CARMA TherapeuticsSM we are motivated to bring the power of adoptive cellular immunotherapy to the large number of solid tumor patients, approximately 500,000 per year in the United States alone, for whom cancer progresses despite surgery, chemotherapy, radiation, or, increasingly, targeted small molecule therapeutics.
Bruce A. Peacock, Executive Chairman
Bruce has held senior executive positions with a number of biotechnology, medical device, and service organizations focused on healthcare including CEO of The Little Clinic, a medical care services company, President and Chief Executive Officer and director of Adolor Corporation, President and Chief Executive Officer and director of Orthovita, Inc., Executive Vice President, Chief Operating Officer and director of Cephalon, Inc., and Senior Vice President and CFO of Centocor, Inc.
Bruce joined Ophthotech Corporation in 2010 and served as Chief Business Officer until September 2014. He now serves as a director of Dicerna Pharmaceuticals, Discovery Laboratories, Invisible Sentinel, Ocular Therapeutics and PanOptica.
Bruce holds a BA degree from Villanova University.
Saar Gill, MD, PhD, Co-Founder
Saar obtained his medical degree and PhD in immunology from the University of Melbourne in Australia and completed a post-doctoral fellowship in cellular therapy at Stanford University. He is now Assistant Professor of Medicine at the University of Pennsylvania where he specializes in the treatment of patients with leukemia and in bone marrow transplantation.
Saar leads two clinical trials of chimeric antigen receptor (CAR) T cell trials for leukemia, based on concepts that were developed in his laboratory. The Gill research laboratory focuses on the interface between adoptive cellular therapy and genetic engineering and is translating the lessons learned from the CAR T cell experience to other immune cell subtypes.
Michael Klichinsky, PharmD, Co-Founder
Michael is a PhD Candidate in the Department of Systems Pharmacology and Translational Therapeutics at the University of Pennsylvania Perelman School of Medicine. He developed CARMA for his doctoral thesis under the co-mentorship of Saar Gill, MD, PhD and Carl June, MD. Michael previously earned a Doctor of Pharmacy degree from the University of Sciences in Philadelphia, graduating Magna Cum Laude. Michael’s scientific expertise is in the field of genetic engineering and immunology, with a focus on chimeric antigen receptor technologies.
Dora Mitchell, PhD, Director
Dora manages the therapeutics and diagnostics company portfolio at PCI Ventures at the University of Pennsylvania. She focuses her efforts on turning scientific inventions into successful businesses. Dora has created various entrepreneurship support services to advance the startup culture at Penn, and often serves as a mentor to young companies and startup competitions in the US and the EU. She currently serves on the boards of Cytovas LLC, Lignamed LLC, Linnaeus Therapeutics, Inc. and Chip Diagnostics Inc.
Prior to joining PCI Ventures, Dora led preclinical development at NellOne Therapeutics, Inc. and was a member of the Health and Life Sciences team at Battelle Ventures, LP focusing on early stage investments.
Dora holds a PhD in Molecular Biology from Princeton University.